EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, Level Up Data

The European Academy of Dermatology and Venereology's 2026 congress produced three atopic dermatitis storylines that Dermatology Times flagged as marquee coverage: the biologic tilrekimig, RAC2 pathway inhibition, and new data from the Level Up program.

The three storylines land inside a treatment landscape that has expanded sharply since dupilumab's 2017 FDA approval opened the IL-4/IL-13 lane. Tralokinumab and lebrikizumab joined the IL-13 class, nemolizumab took IL-31 pruritus, and tezepelumab blocked TSLP. Upadacitinib, abrocitinib, and ritlecitinib added oral JAK coverage for patients who decline or fail biologics.

That density makes every new entrant's differentiation case harder to make at the FDA, EMA, and payer review stages. Among the IL-13 class, head-to-head data and real-world switching studies have begun to define prescriber preference, while JAK inhibitors carry boxed-warning labeling that continues to shape payer step-edits. Pediatric AD coverage has lagged adult approvals, keeping the under-12 population an active target for pipeline programs.

Where does tilrekimig fit?

Tilrekimig headlined EADV 2026's biologic coverage for moderate-to-severe atopic dermatitis. Dermatology Times placed it among the meeting's three top AD storylines, alongside pathway-shifting work on RAC2 and follow-up reads from the Level Up program.

Like its predecessors, tilrekimig lands in a field where regulators and payers will weigh efficacy, dosing convenience, and safety against a standard of care that already includes four mechanism-distinct biologics and three oral JAK inhibitors.

Why does RAC2 inhibition matter?

RAC2, a Rho-family GTPase central to neutrophil and lymphocyte signaling, emerged at EADV 2026 as a novel intracellular approach to AD. Dermatology Times highlighted RAC2 inhibition alongside tilrekimig and Level Up as one of the meeting's three AD cornerstones.

Targeting RAC2 marks a strategic shift away from the extracellular cytokine blockade that defined the post-dupilumab decade, toward intracellular immune modulation where small molecules can intervene before cytokines reach the cell surface.

What does the Level Up program add?

The Level Up study contributed fresh AD data at the congress. Dermatology Times counted Level Up among the marquee EADV 2026 atopic dermatitis highlights.

Programs carrying such monikers typically deliver extension-phase, dose-optimization, or real-world evidence that supplements pivotal trial readouts already on the regulatory record, sharpening payer dossiers and long-term safety profiles that phase 3 trials cannot fully establish.

What's the clinical read-through?

For dermatologists managing refractory eczema, the practical question is whether any of these late-breaking EADV 2026 items translate into new prescribing options, label expansions, or coverage shifts before year's end.

Continued tilrekimig updates, the still-early RAC2 program, and additional Level Up reads will surface through 2026's remaining congresses, including the American Academy of Dermatology and the European Society for Pediatric Dermatology meetings, shaping the next AD guideline revision cycle and the step-therapy sequencing algorithms that have defined biologic use since 2017.